Financial Performance - The company reported a revenue of HKD 49.1 million for the fiscal year ending March 31, 2024, representing a 7.9% increase from HKD 45.5 million in the previous fiscal year[8]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, a decrease of 13.8% compared to a loss of HKD 3.5 million in the previous year[8]. - Basic loss per share for the year was HKD 0.77, down 13.5% from HKD 0.89 in the previous year[8]. - The company experienced over 20% revenue growth in the first half of the fiscal year, although this momentum slowed down later in the year[7]. - The group's revenue increased by HKD 3.6 million or 7.9% to HKD 49.1 million for the year ending March 31, 2024, compared to HKD 45.5 million for the previous year[18]. - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.3%, 19.2%, and 78.5% of total revenue, respectively[15]. Operational Challenges - The company continues to face intense competition and rising operational costs but remains committed to maintaining high standards and competitiveness in its services and products[8]. - The company acknowledges the impact of a slowing Chinese economy and high interest rates on business confidence, affecting consumer spending behavior[7]. - The group anticipates continued challenges due to adverse economic conditions but aims to adapt and monitor market changes proactively[17]. - The company has implemented cost-saving measures and improved operational efficiency to enhance performance amid challenges[8]. Strategic Focus - The company aims to strategically expand and strengthen its market share in Hong Kong and mainland China while enhancing service and product quality[11]. - The company is focused on exploring and launching new services and products to increase market share and identify new business opportunities[9]. - The group introduced new treatment technologies, including EMFACE® Submentum and SYLFIRM X™, enhancing its service offerings[13]. Employee and Cost Management - Employee costs increased by HKD 1.4 million or 6.2% to HKD 24.6 million for the year ending March 31, 2024, due to increased salaries and performance bonuses[22]. - Other expenses rose by HKD 1.4 million or 18.4% to HKD 9.0 million, aligning with the increase in revenue[25]. - Inventory costs for the years ending March 31, 2024, and 2023 were HKD 9.7 million and HKD 8.9 million, representing 19.8% and 19.5% of total revenue, respectively[20]. Shareholder Relations - The company expresses gratitude to shareholders, business partners, suppliers, and customers for their support during the year[9]. - The company did not recommend any final dividend for the year ending March 31, 2024, consistent with 2023[60]. - The company’s distributable reserves as of March 31, 2024, amounted to HKD 1.1 million[71]. Governance and Compliance - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2024, ensuring compliance with applicable accounting standards and GEM listing rules[99]. - The company has adopted corporate governance practices in line with GEM listing rules and has not deviated from the corporate governance code during the fiscal year[108]. - The company has established three committees: the audit committee, the remuneration committee, and the nomination committee, to oversee specific aspects of corporate governance[133]. Environmental, Social, and Governance (ESG) Initiatives - The company’s environmental, social, and governance report covers operations from April 1, 2023, to March 31, 2024, focusing on its medical skin care centers in Hong Kong, which contribute nearly all of its revenue[174][175]. - The total greenhouse gas emissions for the group in 2024 were 50,636 kg CO2 equivalent, a decrease from 52,136 kg in 2023, representing a reduction of approximately 2.9%[198]. - The group has established key performance indicators for measuring its environmental and social performance, ensuring consistency in statistical methods for meaningful comparisons[178]. - The group aims to integrate sustainability into its core business values and continuously review progress against ESG-related goals[183]. Risk Management - The company has implemented a risk management and internal control system, which was reviewed by the audit committee for effectiveness[136]. - The board believes that the internal control measures are adequate to effectively monitor business operations for the fiscal year ending March 31, 2024[153]. - The company has a risk management framework that includes processes for risk identification, analysis, assessment, treatment, and monitoring[151].
密迪斯肌(08307) - 2024 - 年度财报